Selank is another ACTH/MSH-like peptide of the melanocortin class most closely related to the analog tufstin. While traditionally prescribed for anxiety and depression, it has been known to be effective in many other treatments related to immune modulation, anticoagulation, PTSD, ADHD, and metabolic syndromes. Selank has pronounced anxiolytic activity and acts as a stable neuropsychotropic, antidepressant, and anti-stress drug that relieves aggression and fear reaction in different animal species. Selank also has a nootropic action, which positively influences the formation of memory and learning processes, and marked immunomodulatory activity. Clinical studies have shown that the effect of selank is similar to that of tranquilizers at low doses, but is not accompanied by the unwanted side effects of benzodiazepine tranquilizers such as amnesia, withdrawal, or dependence. Experiments have also demonstrated the effectiveness of Selank in preventing the accumulation of body fat (i.e., weight gain) with simultaneous activation of the functional state of the anticoagulation system in development of the metabolic syndrome.Furthermore, decreased blood glucose levels have been observed with chronic treatment of this peptide. The peptide Selank, like the drug Semax, induces anticoagulant and hyperglycemia effects possibly due to the presence of the same amino acid sequence, Pro-Gly-Pro, in its structure. Thus, Selank can be used as a broad-spectrum therapeutic agent for the treatment of the metabolic syndrome. Often prescribed for Anxiolytic, Immune improvement, gastric protection, as a preventative weight gain/metabolic syndrome, and with opioid and alcohol withdrawal/ dependence.
Clinical Research
P-1114 – Rapid and Slow Response During Treatment of Generalized Anxiety Disorder with Peptide Anxiolytic SelankResults: 40% of patients were rapid responders (RR) and characterized by abrupt reduction of whole set of symptoms in first 1-3 Days. At the Day 3 Hamilton Anxiety Rating Scale (HARS) mean total score [SD] reduced from 20.3[11.9] to 7.0[2.9] (p< 0.01). 60% of patients responded gradually(conventional responders – CR). Clinically significant changes of mean HARS total score from 16.1[7.2] to 6.2[4.7] were achieved at Day 14, p< 0.01. In contrast to CR, RR demonstrated obvious EEG-reaction after single dose (900 μg) with increase of beta-rhythm, decrease of theta- and low frequencies of alpha-rhythm (all p< 0.05). Initially, RR and CR significantly differed by the score of asthenic and cognitive symptoms (p< 0.05).Peptide Therapy with Selank, Nasal Spray is available by prescription only. If you think Selank, Nasal Spray may be right for you, schedule a consultation with a member of our Functional Medicine team. You can call us at 718.260.1000 or start by filling out the form below.
